Fabtech Technologies wins Rs 21.0 crore order from CIS country client for medical facility

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights
  • Fabtech Technologies won a Rs 21.0 crore order from a CIS country client for a medical-device facility.
  • The 12-month turnkey project includes cleanroom systems, HVAC, and critical MEP services.
  • Total disclosed order book stands at Rs 149.52 crore across 5 orders in the last 3 quarters.
  • Q1FY27 revenue dropped to Rs 78.20 crore with OPM at 5.63%, down from Q4FY26 levels.
  • Company maintains a strong balance sheet with a current ratio of 2.50x and low leverage.
powered bylight_fuzz_icon
48679961

*this image is generated using AI for illustrative purposes only.

What Happened

Fabtech Technologies has been awarded a confirmed work order valued at Rs 21.0 crore by a customer in a CIS country. The contract covers a turnkey design-and-build project for critical internal infrastructure of an advanced medical-device manufacturing facility. Scope includes integrated engineering, cleanroom systems, HVAC, building management systems, electrical systems, process and clean utilities, laboratory furniture, fire and life-safety systems, installation, testing, and commissioning. The execution timeline is set at 12 months.

Order in Financial Context

The Rs 21.0 crore order represents approximately 19% of the company's average quarterly revenue of Rs 110.30 crore. When viewed against the broader pipeline, the Total Disclosed Order Book (sum of the 5 orders disclosed across the last 3 fiscal quarters shown in the table below) stands at Rs 149.52 crore. This results in a book-to-bill ratio of roughly 0.34x when compared to TTM revenue, indicating that the company is not currently building a large deferred revenue buffer. The existing backlog covers only 1.36 quarters of average quarterly revenue, suggesting that consistent order inflow is necessary to maintain current revenue run-rates.

Company Order Track Record

Order inflow velocity appears to have decelerated in the most recent quarter compared to the heavy concentration seen in Q1FY27. The current order value of Rs 21.0 crore is smaller than the typical per-order size visible in the recent history, where multiple orders in the range of Rs 31.23 crore were booked. The company has received orders from multiple entity types, including domestic clients like Aroma King and international clients in Botswana and CIS countries.

Quarter: Total Order Inflow (Rs Cr): Key Awarding Entities:
Q2FY27 (Jul-Sep 2026) 24.60 Aroma King
Q1FY27 (Apr-Jun 2026) 124.92 Botswana Vaccine Institute Limited, Botswana Veterinary Vaccine Facility, Veterinary Vaccine Manufacturing Facility in Botswana

Execution and Revenue Quality

Revenue execution has shown volatility over the last three quarters. Q4FY26 was a strong quarter with revenue of Rs 168.40 crore and an operating profit margin (OPM) of 14.01%. However, Q1FY27 saw a significant contraction, with revenue dropping to Rs 78.20 crore and OPM compressing to 5.63%. Notably, Q3FY26 recorded a net loss of Rs 5.70 crore and negative OPM of -18.48%, signaling prior execution stress that has since improved but remains unstable.

Quarter: Revenue (Rs Cr): Net Profit (Rs Cr): OPM (%):
Q1FY27 78.20 4.20 5.63%
Q4FY26 168.40 22.10 14.01%
Q3FY26 69.90 -5.70 -18.48%

Revenue Growth - Order Wins Translating to Revenue

As Fabtech technologies has sustained order wins, with a notable spike in inflows during Q1FY27, its annual revenue has grown from Rs 335.90 crore in FY25 to Rs 410.77 crore in FY26, representing a YoY growth of +22.3% based on the latest annual data. Despite this top-line growth, net profit declined by -21.5% in FY26, highlighting margin pressure during the transition phase.

Working Capital and Execution Capacity

The balance sheet provides strong support for execution capacity. With a current ratio of 2.50x, the company holds sufficient liquidity to manage working capital cycles for ongoing projects. The Total Liabilities/Equity ratio stands at a conservative 0.56x, indicating low financial leverage. However, operating cashflow turned negative at -Rs 36.10 crore in FY25, suggesting that while profits are being booked, cash conversion efficiency requires monitoring as receivables or working capital may be stretched.

What to Watch

  • Execution rate: Monitor whether the 12-month timeline for the CIS country order translates into stable quarterly revenue, given the recent dip in Q1FY27.
  • OPM trajectory: The compression from 14.01% in Q4FY26 to 5.63% in Q1FY27 warrants scrutiny; it is important to observe if the new order maintains historical margin quality.
  • Cash conversion: Negative operating cashflow in FY25 indicates potential working capital strain; positive reversal in upcoming quarters will be key.
  • Client concentration: The recent order book includes international vaccine facilities and now a CIS country medical facility; diversification into sectors like flavour manufacturing may reduce sector-specific risks.

Key Observations

  • Margin stress: Net loss of Rs 5.70 crore in Q3FY26; execution stress visible in quarterly data.
  • Valuation check (as of 17 Sep 2026): P/E of 13.3x against ROCE of 31.09%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios.
  • Cash conversion: Operating cashflow of -Rs 36.10 crore in FY25; backlog is not converting to cash efficiently, and receivables or working capital cycle may be stretched.

Historical Stock Returns for Fabtech Technologies

1 Day5 Days1 Month6 Months1 Year5 Years
-2.09%-4.46%-3.76%+2.06%-22.14%-22.14%

Fabtech Technologies secures ₹21 crore turnkey project in CIS country

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Fabtech Technologies has secured a ₹21 crore turnkey project in a CIS country
  • The project involves development of infrastructure for a medical device manufacturing facility
  • Targeted handover for the project is within 12 months
powered bylight_fuzz_icon
51177365

*this image is generated using AI for illustrative purposes only.

Fabtech Technologies has secured a ₹21 crore turnkey project in a CIS country, involving the development of infrastructure for a medical device manufacturing facility.

Project overview

The project entails end-to-end infrastructure development for a medical device manufacturing facility located in a CIS country. The targeted handover for the project is within 12 months of commencement.

Parameter Details
Project value ₹21 crore
Project type Turnkey
Location CIS country
Scope Infrastructure for medical device manufacturing facility
Targeted handover Within 12 months

Historical Stock Returns for Fabtech Technologies

1 Day5 Days1 Month6 Months1 Year5 Years
-2.09%-4.46%-3.76%+2.06%-22.14%-22.14%
Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How does this ₹21 crore contract impact Fabtech Technologies' projected revenue growth for the current fiscal year?

What are the potential currency fluctuation risks associated with executing a project in a CIS country, and how is the company hedging against them?

Does this win signal a broader strategic expansion by Fabtech into the medical infrastructure sector beyond traditional industrial projects?

More News on Fabtech Technologies

1 Year Returns:-22.14%